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Impaired eIF5A function causes a Mendelian
disorder that is partially rescued in model systems
by spermidine
Víctor Faundes 1,2, Martin D. Jennings 3,4, Siobhan Crilly 5, Sarah Legraie1, Sarah E. Withers5,
Sara Cuvertino1, Sally J. Davies6, Andrew G. L. Douglas7,8, Andrew E. Fry6,9, Victoria Harrison7,
Jeanne Amiel10,11,12, Daphné Lehalle10, William G. Newman 1,13, Patricia Newkirk14, Judith Ranells14,
Miranda Splitt 15, Laura A. Cross 16,17, Carol J. Saunders18,19,20, Bonnie R. Sullivan 16,17,
Jorge L. Granadillo21, Christopher T. Gordon 11,12, Paul R. Kasher4,5 ✉, Graham D. Pavitt 3,4 ✉ &
Siddharth Banka 1,13 ✉

The structure of proline prevents it from adopting an optimal position for rapid protein
synthesis. Poly-proline-tract (PPT) associated ribosomal stalling is resolved by highly conserved eIF5A, the only protein to contain the amino acid hypusine. We show that de novo
heterozygous EIF5A variants cause a disorder characterized by variable combinations of
developmental delay, microcephaly, micrognathia and dysmorphism. Yeast growth assays,
polysome proﬁling, total/hypusinated eIF5A levels and PPT-reporters studies reveal that the
variants impair eIF5A function, reduce eIF5A-ribosome interactions and impair the synthesis
of PPT-containing proteins. Supplementation with 1 mM spermidine partially corrects the
yeast growth defects, improves the polysome proﬁles and restores expression of PPT
reporters. In zebraﬁsh, knockdown eif5a partly recapitulates the human phenotype that can
be rescued with 1 µM spermidine supplementation. In summary, we uncover the role of eIF5A
in human development and disease, demonstrate the mechanistic complexity of EIF5A-related
disorder and raise possibilities for its treatment.

A list of author afﬁliations appears at the end of the paper.
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roline is a unique amino acid as its amine nitrogen is bonded
to two, instead of one, carbon atoms with a distinctive rigid
cyclic structure that prevents it from adopting an optimal
position required for rapid protein synthesis1. The presence of
proline, either as a peptidyl donor or an acceptor, impedes the rate
of peptide bond formation by the ribosome, an inhibitory effect
that becomes progressively stronger, to the extent that three or
more consecutive prolines provoke ribosome stalling2–4. In
eukaryotic cells, ribosomal stalling is resolved by the Eukaryotic
Translation Initiation Factor 5A (eIF5A), which is critical for the
synthesis of peptide bonds between consecutive proline residues5.
Notably, the frequency of poly-proline tracts (PPTs) is higher in
evolutionarily new proteins and of all tandem amino acid repeats,
only the proline repeat frequency correlates with functional
complexity of eukaryotic organisms6. eIF5A1 (hereafter eIF5A)
and its normally undetectable paralogue eIF5A2 are the only
human proteins that contain the amino acid hypusine, a posttranslationally modiﬁed lysine at position 50 (K50)2–4. Hypusine is
synthesised from spermidine, a polyamine, via two sequential
enzymatic steps involving highly conserved deoxyhypusine
synthase (DHPS) and deoxyhypusine hydroxylase (DOHH)
enzymes7. Hypusinated eIF5A stabilises P-tRNA that facilitates
peptide bond formation at stalled ribosomes5. Other functions of
eIF5A include recognition of the correct start codon8,9, global
protein synthesis elongation and termination10,11, promoting the
elongation of many non-poly-proline-speciﬁc tripeptide sequences, and eliciting nonsense-mediated decay (NMD)12. It is essential for cell viability and growth in both simple2,5 and complex3
organisms. Somatic overexpression of EIF5A has unfavourable
prognostic implications in several cancers, including pancreatic,
lung, hepatocellular, bladder, and colorectal carcinomas13,14.
However, no human phenotype has been previously attributed to
germline EIF5A variants.
Here, we demonstrate that de novo heterozygous EIF5A variants cause a previously undescribed syndrome characterised by
variable combinations of developmental delay, microcephaly,
micrognathia, congenital malformations and dysmorphism.
These variants likely result in the loss of eIF5A function through
distinct mechanisms and lead to impaired interaction between
eIF5A and ribosomes. Both functional and phenotypic consequences of impaired eIF5A activity are partially rescued by
spermidine supplementation in yeast and zebraﬁsh models.
Results
Germline variants in EIF5A cause a previously undescribed
craniofacial-neurodevelopmental disorder. In an individual with
intellectual disability, congenital microcephaly, micrognathia and
clinical suspicion of a Kabuki syndrome (MIM # 147920)-like
condition15, we identiﬁed a de novo heterozygous frameshift variant
in EIF5A (c.324dupA, p.R109Tfs*8) by trio whole-exome sequencing (Fig. 1a–c, Table 1, individual #3, and Supplementary Note 1).
EIF5A has four protein-coding transcripts, but ENST00000336458/
NM_001970.5 (Uniprot P63241) is preferentially, widely and most
highly expressed in all adult human tissues16–18. Only one truncating variant has been recorded in gnomAD, a variant sequence
database of >140,000 control individuals, in this transcript (gnomAD o/eLoF = 0.11; pLI = 0.74)19. Also, the GeVIR metrics (GeVIR
AD = 4.38; VIRLoF AD = 2.21) add supportive evidence that
EIF5A is highly likely to be associated with autosomal dominant
disease20. Hence, we concluded that the EIF5A variant identiﬁed in
individual #3 was signiﬁcant. Through Matchmaker Exchange21
and GeneMatcher22 we identiﬁed six additional individuals with
nonsense or missense de novo EIF5A variants (c.143C>A, p.T48N;
c.316G>A, p.G106R; c.325C>G, p.R109G; c.325C>T, pR109*;
c.343C>T, p.P115S; c.364G>A, p.E122K). The missense variants are
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located in one of the most constrained coding regions of the human
genome (>99th percentile)23, and affect residues that are highly
evolutionarily conserved (Fig. 1b, c). In silico modelling of missense
variants (Fig. 1d) onto the structure of yeast eIF5A in complex with
the 60S ribosome (PDB entry 5GAK)24 shows that the missense
variants affect surface-exposed residues. T48 is adjacent to the
hypusinated lysine 50, G106 and R109 residues are close to the
ribosomal protein uL1 and E122 is close to the P-site tRNA. In
contrast, P115 has no clear intermolecular interactions. Although
the individuals were identiﬁed via their genotypes, on reverse
phenotyping25 their clinical features showed remarkable convergence. All patients were affected by variable degrees of developmental delay and/or intellectual disability, microcephaly (either
absolute or relative) and overlapping facial dysmorphisms (Table 1,
Fig. 1a and Supplementary Note 1). Notably, four individuals in this
cohort were clinically suspected to have either a Kabuki syndromelike or a mandibulofacial dysostosis (MIM #154400)-like condition
(Table 1 and Supplementary Note 1). eif5a/Eif5a mRNA is highly
expressed in Danio rerio (hereafter zebraﬁsh)26 and Mus musculus27 (hereafter mouse) embryos in structures that form the brain
and mouth, thus corresponding with the most signiﬁcantly
impacted structures in the affected individuals. Overall, these results
are strongly indicative of the frameshift, nonsense and missense
EIF5A variants being causal for the phenotypes of the affected
individuals.
EIF5A variants impair eIF5A function. Peripheral blood
mononuclear cells obtained from Individual 3, with the EIF5A
frameshift variant c.324dupA, and two healthy controls were
transformed by Epstein-Barr virus into lymphoblastoid cell lines
(LCLs). Blood samples from other affected individuals were not
available. The EIF5A mRNA level in LCLs was signiﬁcantly
reduced in Individual 3 (Fig. 1e) and the transcript with
c.324dupA was not detected (Supplementary Fig. 1), suggesting
NMD of the mutant transcript.
The Saccharomyces cerevisiae (yeast) and human eIF5A share a
very high degree of conservation (62% identity/92% similar)
(Fig. 1b) and well-established assays to investigate eIF5A function
in yeast are available2,5. We synthesised a human EIF5A cDNA
(heIF5A hereafter) optimised for yeast codon usage, and added
the 5′ and 3′ control regions of the yeast homologue of EIF5A
(known as TIF51A or HYP2, yeIF5A hereafter) (Supplementary
Note 2 and Supplementary Table 1). Introduction of this
construct on a centromeric plasmid using standard techniques
in a yeast strain in which both TIF51A and TIF51B (a second
yeIF5A gene that is transcribed only in anaerobic conditions2) are
deleted (Supplementary Table 3 and Supplementary Fig. 2)
restored its growth potential similar to the wild-type yeIF5A
(Fig. 2a, rows 1 and 3). This conﬁrmed that the synthetic heIF5A
can replace yeIF5A functions in line with previous reports28.
Next, we performed site-directed mutagenesis to create heIF5A
constructs with the p.T48N, p.G106R, p.R109Tfs*8 and p.E122K
variants in centromeric plasmids (Supplementary Tables 1 and 2).
The individuals with the p.R109G, p.R109* and p.P115S variants
were identiﬁed after experiments for other variants were concluded
and, therefore, these variants were not included in the functional
studies. Yeast colonies expressing the heIF5A-R109Tfs*8 as the sole
source of eIF5A could not be obtained after ten days of growth, and
across multiple plasmid shufﬂing experiments (Supplementary
Figs. 2 and 3). Western blotting (WB) using a monoclonal antihuman eIF5A and an anti-hypusinated eIF5A antibody (hereafter
hypusine) of pre-shufﬂed heIF5A-R109Tfs*8 strains co-expressing
heIF5A-WT revealed that p.R109Tfs*8 was poorly expressed, and
even when expressed in high-copy it was very poorly hypusinated
(Supplementary Fig. 4). The poor expression of this mutant in yeast
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Fig. 1 Heterozygous variants in EIF5A cause a novel craniofacial-neurodevelopmental disorder. a Individuals with de novo heterozygous missense
(individuals 1, 2, 4 and 7) or frameshift (individual 3) EIF5A variants display similar facial dysmorphism, microcephaly and micrognathia. Photographs of
individuals 5 and 6 are not available. b The missense EIF5A variants affect highly conserved residues. Evolutionary conservation of residues affected by
variants (delimited by yellow rectangles) is shown in ﬁve species. BLOSUM62 scores are depicted in purple scale (dark purple = completely conserved,
light purple = relatively conserved, white = not conserved). Lysine (K) 50 is hypusinated (Hyp). c The EIF5A variants are novel and located in the functional
sites and domains of eIF5A. Top: hypusine site (HS) is the orange bar between residues 48 and 55 (InterPro entry P63241), and the OB fold domain is the
cyan bar between residues 83 and 150 (InterPro entry P63241). Bottom: the location and the minor allele frequencies (MAF) of high quality non-ﬂagged
missense variants (yellow triangles) and a protein-truncating variant (p.N28Mfs*64, magenta line) seen only in controls of gnomAD v2.1.1 for the transcript
ENST00000336458. d In silico modelling of missense variants supports their deleterious nature. Variants are indicated as red spheres at the surface of
yeast eIF5A (semi-transparent gold) with hypusinated K51 (human K50, hK50) (black spheres) shown bound to the yeast 60S ribosomal subunit E site
(grey secondary structures only, with uL1 in blue), with adjacent P-site (green) and A-site (pink) tRNAs (PDB entry 5gak). Note that T48 (yeast T49,
yT49) is in proximity to the hypusinated hK50; hG106 (yG107) and hR109 (yK110) are close to uL1 and hE122 (yS123) is close to the P-site tRNA. e The
mutant EIF5A transcript with the truncating variant is not expressed. The mRNA levels in lymphoblastoid cells from individual 3 compared to control 1
(healthy female) and control 2 (healthy male) are shown relative to GAPDH (2−ΔCT method). Each data point corresponds to one technical replicates, and
the bars show the mean + SEM. Two-sided P values were determined by unpaired t-test.

is consistent with our inability to detect this protein in LCLs from
individual 3. In contrast, the three missense mutations each
supported yeast growth as the sole source of eIF5A showing that
they retain sufﬁcient eIF5A function for cell viability. The heIF5AT48N and heIF5A-G106R yeast cells exhibited slow growth (Fig. 2a,
rows 4 and 5), similar to a previously characterised temperaturesensitive mutant yeIF5A-S149P mutant (Fig. 2a, row 2)2,5. No
signiﬁcant difference was observed between growth of heIF5AE122K and heIF5A-WT (Fig. 2a, rows 6). These results indicate that
the p.T48N and p.G106R variants result in partial loss of eIF5A
function, and p.R109Tfs*8 variant results in complete loss of
viability. However, the impact of the p.E122K variant remained
uncertain.

EIF5A variants reduce eIF5A–ribosome interaction through
different mechanisms. Next, we asked if the missense variants
affected interaction of heIF5A with ribosomes through polysome
proﬁling (Supplementary Fig. 5). All missense variants that were
tested, including the p.E122K variant, exhibited aberrant polysome proﬁles, with elevated polysome-to-monosome (P/M) ratios
and an increase in the free 60S peak heights and the 60 S/80S
ratios (Fig. 2c), consistent with a global translation elongation
defect2,5. Probing for eIF5A and hypusine across polysome
fractions revealed that WT eIF5A has ribosome-free (lanes 1–2 in
Fig. 2c) and 80S (lane 6 in Fig. 2c) peaks. In contrast, each
missense mutant showed a reduction in the 80S ribosome fraction
(Fig. 2c), indicating a reduction in ribosome binding by each
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Moderate/severe
No

No
Yes
Hemivertebrae (L3)

DD/ID
CNS anomalies

Physical anomalies
Heart
Craniofacial
Other

Mandibulofacial
dysostosis like

No
No
Constipation
Gastroesophageal
reﬂux Gastrostomy
Kabuki
syndrome like

Yes
Yes
Yes
Yes
Yes
Yes
Yes
Hypertelorism

Yes
Yes
No
Yes
No
Yes
Yes
Lower eyelid
hypoplasia

No
Yes
No

SS (−2.82)
LW (−2.28)
Mi (−7.47)

N (0.53)
OW (2)
Mi (−3)

Yes
No
No

Kabuki syndrome like

Yes
No
Conductive deafness
Premature thelarche

Yes
Yes
Yes
Yes
Yes
Yes
No
No

N (0.86)
N (−0.41)
Mi (−2.11)

Yes
Yes
No

Yes
No
Yes
Cardiac anomalies
Cleft palate
Mild
No

3
F (8.4 y)
17:7214722
c.324dupA p.R109Tfs*8
DN Het

Kabuki syndrome like

Yes
Yes
Constipation

Yes
Yes
Yes
Yes
Yes
Yes
No
Prominent long ears

N (−0.45)
N (0.06)
Mi (−2.62)

Unknown
Yes
Cryptorchidism
Pes planus

Moderate
Peritrigonal
hyperintensities

Unknown
Yes
Yes
Hypotonia

4
M (18.3 y)
17:7214723
c.325C>G p.R109G
DN Het

Mowat Wilson like

N/A
No
Dysphagia Gastrostomy
Failure to thrive

No
No
Yes
No
Yes
No
No
Plagiocephaly Sparse
scalp hair Frontal bossing
Downslanting PF
Cupped ears

N (−1.45)
LW (−3.14)
N (−0.45)

Yes
Yes
No

No
No
Yes
Cardiac anomalies
Hypotonia
Moderate
No

5
M (8 mo)
17:7214723
c.325C>T p.R109*
DN Het

None

No
Yes
Hypotonia Flat feet

Yes
No
No
No
No
Yes
No
Long PF hypoplastic
ala nasi

N (+1 SD),
N (−0.09 SD)
N (−1.09)

Unknown
No
No

Mild/Moderate
Left lateral
ventriculomegaly

No
No
No
No

6
M (4 y)
17:7214741
c.343C>T p.P115S
DN Het

Yes
Yes
Autism ADHD
Delayed puberty
Nasal polyps
None

No
No
Yes
No
No
No
Yes
Deep-set eyes Abn.
lower eyelids
Small ears

SS (−2.59)
N (−0.69)
Mi (−1.94)

Unknown
No
Toe contractures
Small toenails
Pes planus

Moderate
No

Unknown
No
No
Foetal ascites

7
F (16.4 y)
17:7214762
c.364G>A p.E122K
DN Het

Abn abnormal, ADHD attention deﬁcit hyperactivity disorder, CNS central nervous system, DD developmental delay, HC head circumference, Het heterozygous, ID intellectual disability, IUGR intra-uterine growth retardation, LW low weight, Mi microcephaly, N within normal
ranges, N/A not applicable, OW overweight, PF palpebral ﬁssures, SD standard deviation, SS short stature.
aAt last examination.
bAccording to hg19.
cGenBank reference NM_001970.5, Ensembl reference ENST00000336458.
dUniProtKB reference P63241-1.

Initial clinical suspicion

Other medical issues
Joint hypermobility
Eye anomalies
Others

Growth parameters
Height (SD)
Weight (SD)
HC (SD)
Facial dysmorphisms
Broad eyebrows
Abn. supraorbital ridges
Epi/telecanthus
Bulbous nasal tip
Thin upper lip
Micrognathia
Low set ears
Other

Yes
Yes
Yes
Cardiac anomalies

Yes
Yes
No
No
Moderate
No

2
F (8.4 y)
17:7214714
c.316G>A p.G106R
DN Het

1
F (6.9 y)
17:7213097
c.143C>A p.T48N
DN Het

Individual

Sex (age)a
Genomic positionb
cDNAc protein consequenced
Inheritance/zygosity
Perinatal history
Congenital microcephaly
IUGR
Feeding difﬁculties
Other

Characteristics

Table 1 Phenotypes of patients with EIF5A variants.
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mutant eIF5A, consistent with the idea that impaired
eIF5A–ribosome interactions impact translation elongation of
each mutant.
To explore possible mechanisms for the reduction in ribosome
binding of missense variants, we performed WB. In cells
expressing heIF5A-T48N, levels of total eIF5A were normal, but
levels of hypusination were reduced, suggesting that the p.T48N
impairs hypusination of the adjacent K50 residue. As hypusination is necessary for eIF5A function, reduced hypusination may
contribute to the observed reduction in ribosome association. In
contrast, total levels of eIF5A were modestly reduced in heIF5AG106R and heIF5A-E122K cells, while hypusination was
unaffected (Fig. 2b). Overall, these results indicated that EIF5A
variants reduce eIF5A–ribosome interaction, likely through
different mechanisms.

ARTICLE

EIF5A variants impair synthesis of proteins with PPTs. Next,
we examined if impaired eIF5A function impacted on translation
of speciﬁc mRNAs. Because eIF5A is especially critical for the
optimal synthesis of proteins containing PPTs2,5, we studied
expression of two previously described PPT reporters—a haemagglutinin (HA)-tagged Ldb17 with a single long PPT of nine
consecutive prolines and HA-Eap1 with three shorter PPTs
(Supplementary Tables 1 and 3 and Fig. 2d)5. As these reporters
require expression with galactose as a carbon source, we ﬁrst
evaluated whether levels of eIF5A and hypusination in these cell
growth conditions were consistent with our previous ﬁndings.
Here in both of the slow-growing mutants (p.T48N and p.G106R)
expression of eIF5A was lower than WT. As previously, hypusination was consistently low for p.T48N (Supplementary Figs. 6
and 7). By WB of total cell extracts we observed decreased levels
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Fig. 2 EIF5A variants impair eIF5A function, its interaction with ribosome and synthesis of proteins with poly-proline tracts. a Variants p.T48N and
p.G106R affect yeast growth. Representative serial dilution growth assay of yeast strains for human eIF5A (heIF5A) and its variants, compared to the
growth of strains with WT yeast eIF5A (yeIF5A) or the thermosensitive yeIF5A-S149P after 2 days. Eighteen replicates per temperature were performed.
b Variant p.T48N reduces eIF5A hypusination, whereas p.G106R and p.E122K decrease eIF5A levels. eIF5A expression (left) and hypusination (Hyp; right)
among yeast strains with missense heIF5A variants, grown at 30 °C in synthetic complete (SC) liquid medium. Each data point corresponds to one
biological replicate, which was controlled as stated in the ‘Methods' (see Eq. (1)), and the bars show the mean + SEM. Two-sided P values were determined
by unpaired t-test. Full uncropped images of gel blots are shown in Supplementary Fig. 9. c Missense mutants decrease eIF5A interaction with ribosome.
Polysome proﬁles of yeast expressing either heIF5A-WT or missense variants, grown at 30 °C in SC medium. Corresponding western blot analyses of
eIF5A, hypusine, and the ribosomal proteins uS3 and uL29 probed across gradient fractions for each polysome proﬁle are presented beneath. Polysome-tomonosome (P/M) and 60/80S ratios for the A260 traces are given, calculated by comparing the areas under the 80S and polysome peaks. In addition, the
fraction of total eIF5A signal associated with the 80S (western blot lane 6) is given. Full uncropped images of gel blots are shown in Supplementary Fig. 10.
One proﬁle was performed. d Missense mutants decrease synthesis of reporters with poly-proline tracts. Comparison of Ldb17 (left graph) and Eap1 (right
graph) poly-proline-containing reporter expression in heIF5A yeast strains grown at 30 °C in SCGal medium. Data presentation and statistical treatment as
described for panel b. Full uncropped images of gel blots are shown in Supplementary Fig. 11. e Genes with the highest numbers of prolines match the initial
clinical suspicion for studied individuals. Enrichment of PPTs in MAGs. For each MAG the number of PPTs (X-axis) is plotted against the number of
prolines in the longest PPT (Y-axis). MAG circle size represents the total number of prolines in PPTs in each protein. The ‘top 10’ ranked MAGs are named.
Heterozygous loss-of-function variants in SF3B4 and KMT2D (both underlined) cause acrofacial dysostosis 1, Nager type (a subtype of mandibulofacial
dysostosis, MIM #154400) and Kabuki syndrome 1 (MIM #147920), respectively, which overlap with the initial clinical suspicions in individual 1, and for
individuals 2 to 4, respectively.

of both PPT reporters for the p.T48N and p.G106R alleles
(Fig. 2d). Although levels of Ldb17 in the p.E122K variant were
typically lower than in WT cells, this did not reach statistical
signiﬁcance (Fig. 2d and Supplementary Fig. 7). Hence, the
human eIF5A variants impair the synthesis of proteins containing
PPTs in yeast.
Human microcephaly-associated genes (MAGs) are enriched
for PPTs. Next, we explored if impaired synthesis of proteins
with PPTs could help explain microcephaly, which was the most
consistent feature of our patients. To study this, we prepared a
catalogue of all known human MAGs according to OMIM and
assessed their PPT content29,30 (Supplementary Data 1). We
observed that 198/685 (28.9%) MAGs and 4366/17981 (24.2%) of
all other human protein-coding genes have ≥1 PPT [χ2 7.64;
OR = 1.27; 95% CI 1.07–1.5; P = 0.0057]). Next we ranked MAGs
according to their proline content in PPTs (Supplementary
Data 1 and Fig. 2e). KMT2D was ranked as #1 in this list. Loss-offunction KMT2D variants cause Kabuki syndrome31, which was
the clinically suspected diagnosis in three individuals. SF3B4,
variants in which cause acrofacial dysostosis 1, Nager type32
(phenotypic overlap with the clinical suspicion in individual 1),
was ranked #5 (Table 1 and Fig. 2e).
Spermidine partially rescues impaired eIF5A function in yeast.
Polyamines contribute to the efﬁciency and ﬁdelity of protein
synthesis, and spermidine may overcome absence of eIF5A to
some extent to promote peptide synthesis33. Furthermore, DHPS
mediated transfer of a 4-aminobutyl moiety from a polyamine,
spermidine, to K50 is the ﬁrst step in formation of active hypusinated eIF5A34. Previous work has demonstrated that spermidine promotes longevity in yeast, whereas depletion of
polyamines has a deleterious effect35. We therefore reasoned that
spermidine supplementation could potentially overcome the
effects of impaired eIF5A function. In addition, because p.T48N
hypusination was reduced, it may indicate that polyamine concentrations were limiting for hypusination in our growth conditions. We screened the effect of supplementing growth medium
with different concentrations of spermidine on yeast growth, as
measured by the rate of colony formation (Fig. 3a and Supplementary Fig. 8). One millimolar spermidine partially corrected
the growth defects of p.T48N and p.G106R cells (Fig. 3a). As a
growth phenotype was not observed in yeast expressing the
6

p.E122K variant, this assay was uninformative for this allele.
Higher spermidine concentrations had progressively deleterious
effects impairing the growth of all strains (Fig. 3a and Supplementary Fig. 8).
Next, we performed polysome proﬁling of WT, p.T48N and p.
G106R cells in the presence of 1 mM spermidine. Spermidine
treatment improved the global polysome proﬁles for both mutant
strains with no impact on heIF5A-WT (compare Fig. 3b with
Fig. 2c). We observed full or partial restoration of heIF5A
interaction with the 80S ribosome in p.T48N and p.G106R cells,
respectively (Fig. 3b). Furthermore, 1 mM spermidine restored
expression of PPT reporter in both growth-rescued mutants
(Fig. 3c, left graph). However, improved growth and protein
synthesis was not explained by improved eIF5A expression levels
or by enhanced hypusination of p.T48N mutant eIF5A (Fig. 3c,
middle and right graph). These results suggest that spermidine
can rescue and/or bypass impaired eIF5A functions in protein
synthesis independent of its role as a substrate for hypusination of
eIF5A K50 (ref. 33).
Spermidine partially rescues phenotypes of impaired eIF5A
function in a zebraﬁsh model. We next investigated if spermidine can rescue the impact of loss of eIF5A function in a developing vertebrate model. Zebraﬁsh eif5a shares a high degree of
conservation with its human orthologue (74% identity, 86%
similarity) (Fig. 1b). Previous studies have demonstrated that
morpholino-mediated knockdown of eif5a or transient overexpression of human EIF5A can cause microcephaly in zebraﬁsh
larvae36. We used a validated and published splice site morpholino (MO)36 to knockdown eif5a in fertilised nacre37 zebraﬁsh
eggs, which were incubated in a standard, spermidine-free medium. The resulting larvae were ﬁxed and cartilage was stained at
77 h post-fertilisation (hpf). In line with the human disorder
phenotypes, we measured the distance between irises (translating
to head circumference and therefore serving as a model for
microcephaly) and the length of mandible cartilages (translating
to mandibular growth and therefore serving as a model for
micrognathia) (Fig. 4a, left and right photographs, respectively).
Although we did not recapitulate the previously described
microcephaly phenotype36 (Fig. 4b, c, left graph), the eif5a MO
induced micrognathia in zebraﬁsh larvae (Fig. 4b, c, right graph).
Next, we explored the effects on zebraﬁsh of supplementation
with 10-fold dilutions (from 1 mM to 0.1 µM) of spermidine. One
hundred micromolar or higher concentrations killed larvae before
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Fig. 3 Spermidine partially rescues impaired eIF5A function phenotypes in yeast. a Spermidine rescues growth of p.T48N and p.G106R strains. Growth
of yeast strains for the human eIF5A (heIF5A) and the missense variants in minimum media supplemented with 0 (Untreated), 1 and 2 mM of spermidine
at 30 °C. Eighteen replicates per temperature were performed. b Spermidine increases the interaction of heIF5A-T48N and heIF5A-G106R with ribosomes.
Polysome proﬁles of heIF5A-WT, heIF5A-T48N and heIF5A-G106R grown at 30 °C in SC with 1 mM spermidine. Corresponding western blot analyses as
described in the legend to Fig. 2c. Full uncropped images of gel blots are shown in Supplementary Fig. 12. One proﬁle was performed. c Spermidine
increases the synthesis of Ldb17 reporter in both p.T48N and p.G106R strains. Comparison of Ldb17 (left graph), total eIF5A (middle graph) and
hypusinated eIF5A (right graph) among heIF5A yeast strains, grown at 30 °C in SCGal with and without 1 mM spermidine. Data presentation and statistics
as described in the legend to Fig. 2b. Full uncropped images of gel blots are shown in Supplementary Fig. 13.

ﬁxation. Supplementation with 1 µM spermidine resulted in
partial rescue of micrognathia when compared to control MO
(Fig. 4b, c, right graph), demonstrating that spermidine supplementation can rescue this developmental defect by bypassing loss
of eIF5A. Thus, endogenous concentrations of spermidine within
the yolk are not sufﬁcient to overcome loss of eIF5A and spermidine supplementation is likely able to promote peptide
synthesis to rescue this developmental defect33.
Discussion
EIF5A is a unique and critical gene for synthesis of proteins,
especially those with PPTs. It is highly intolerant to variation, but
so far no human condition caused by variants in this gene has
been identiﬁed. We deﬁne a previously undescribed human disorder caused by heterozygous EIF5A variants. This is supported
by high constraint for deleterious EIF5A variants in population
databases, the de novo nature of all the variants described here,
their absence from population databases along with high evolutionary conservation and the phenotypic similarity of patients
ascertained via their genotypes (Fig. 1a–c). The disorder can be
caused by protein truncating or missense variants. Of note, the
codon encoding Arg109 was impacted in three out of seven cases.
In humans, this amino acid is encoded by a CpG including codon
(CGA) that may be prone to methylation, deamination and CGTA transition, each of which could explain clustering of the

mutations seen in this study38. The phenotype of the condition
consists of variable degrees of developmental delay, intellectual
disability, microcephaly and craniofacial dysmorphism, including
micrognathia (Table 1, Fig. 1a and Supplementary Note 1).
Although both EIF5A and EIF5A2 are hypusinated and widely
expressed in adult human tissues, the expression of the former is
~20-fold higher in brain structures than the latter16. While
Eif5agt/gt mice are embryonically lethal3, Eif5a2−/− mice are
viable and display normal development39. Therefore, EIF5A2
expression may not be sufﬁcient to compensate the loss of EIF5A
function16. Pathogenic variants in eIF2B subunits (EIF2B1,
EIF2B2, EIF2B3, EIF2B4 and EIF2B5; MIM #603896)40, EIF2S3
(MIM #300148)41, EIF3F (MIM # 618295)42, EIF4E (MIM
#615091)43–45 and EIF4G1 (MIM #614251)46 have been previously described to cause distinct neurological disorders. Our
ﬁndings add to this list of translation factors implicated in human
developmental disorders.
Yeast growth assays showed the deleterious nature of the
truncating and p.T48N and p.G106R missense EIF5A variants
(Fig. 2a). Our results with the truncating variant are concordant
with a previous study that demonstrated that deletion of either
eIF5A amino- or carboxy-termini were lethal in yeast28. For all
studied missense variants, including the E122K variant, the
polysome proﬁles were abnormal further indicating their deleterious nature. More speciﬁcally, the higher P/M ratios typically
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Fig. 4 Knockdown of eif5a in zebraﬁsh embryos induces micrognathia, which can be partially rescued by spermidine. a Measurement of iris distance
was used for assessing head size (left photograph), and both Meckel’s (M) plus both palatoquadrate (Pq) cartilages for mandible assessment (right
photograph). b Spermidine partially rescues micrognathia. Representative images of alcian blue-stained zebraﬁsh larvae injected with 400 pg (1 nL) of
either control or eif5a MOs. Larvae were incubated at 28 °C for 3 h in standard E3 embryo medium (SE3EM) and then transferred to either fresh SE3EM or
fresh SE3EM plus 1 µM spermidine at 28 °C, and processed after 77 h post-fertilisation. c Quantiﬁcation of measurements shown in panel a. Each data point
corresponds to one ﬁsh, the longer horizontal line represents the median, whereas the shorter horizontal lines are the 25th and 75th percentiles. P values
were determined by Kruskal Wallis test with multiple comparisons. P values for comparisons against control MO injected ﬁsh are provided when less
than 0.05.

indicate a reduction in translation elongation rates or pausing of
ribosomes causing ‘trafﬁc jams’ on individual mRNAs leading to
increased ribosome accumulation on mRNAs. The increase in the
free 60S peak heights and the 60S/80S ratios (Fig. 2c) suggests
that EIF5A missense variants may result in delay of 60S joining
during initiation, or reduce the stability of 80S complexes. Both
defects are consistent with the known functions of eIF5A in stimulating the ﬁrst peptide bond formation and later during
elongation and demonstrate clearly that each eIF5A missense
mutation impacts protein synthesis globally2.
Absence of the mutant transcript with the c.324dupA variant
and lower level of EIF5A mRNA levels in the LCLs of individual
3 suggest haploinsufﬁciency as the underlying mechanism for the
protein truncating variant. This is supported by phenotypic
overlap of intellectual disability, microcephaly and retrognathia in
patients with 17p13.1 microdeletions that encompass EIF5A47.
Notably, the minimum critical region of this 17p13.1 microdeletion syndrome includes 17 protein-coding genes and its main
phenotypic driver has not been resolved. Our observations suggest that haploinsufﬁciency of EIF5A could be responsible for the
phenotype of 17p13.1 microdeletion syndrome.
The loss of function of the EIF5A missense variants is likely to
be due to different mechanisms. The observation of reduced
hypusination in cells expressing the p.T48N variant suggests that
this variant impairs hypusination of the adjacent K50 residue.
Other missense mutations changing residues adjacent to K50 also
8

have reduced hypusination28, consistent with the idea that they
impair interactions with DHPS and/or DOHH enzymes responsible for hypusination. This is also supported by our spermidine
supplementation experiment (Fig. 3) that showed no improvement of p.T48N hypusination, indicating that spermidine levels
are not a limiting factor for hypusination of this mutant. The
DHPS molecular structure indicates that the surface surrounding
its active site tunnel is highly acidic48, while the eIF5A surface
region around K50 has a complementary positive charged. In
silico modelling (Fig. 1d) of the variant structure suggests T48N
modestly increases the positive charge, but if or how this affects
DHPS or DOHH interactions with eIF5A will require further
experimentation. Reduction of total eIF5A levels in mutant cells
(Figs. 2b and 3c) could be indicative of reduced protein or mRNA
stability, but reduced protein levels per se are unlikely sufﬁcient to
explain the mutant phenotype. Instead our polysomal proﬁle
results are indicative of reduced interaction of eIF5A with ribosomes (Fig. 2c) as the common mechanism in the yeast model. As
we did not have access to patient cells we could not test mRNA
and protein expression levels or functional changes in individuals
with the missense variants. Therefore, we cannot rule out that
other mechanisms such as abnormal splicing or mRNA degradation may contribute to the disorder in individuals with missense EIF5A variants. Identiﬁcation of more individuals in the
future with disease-causing variants in this gene will be of great
interest to uncover the underlying mechanisms.
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We demonstrated that the loss of eIF5A function resulting
from the variants has a deleterious impact on synthesis of proteins with PPT (Fig. 2d). The reduction was statistically signiﬁcant for p.T48N and p.G106R variants. Although we did
observe a reduction for the p.E122K variant, it did not reach
statistical signiﬁcance. In all our assays p.E122K was the least
affected mutant. This is consistent with the milder individual
phenotype of the patient harbouring this variant (Table 1 and
Fig. 1a). Human KMT2D and SF3B4 are two MAGs that encode
proteins with one of the highest number of PPTs (Fig. 2e).
Interestingly, the phenotypes resulting from their loss of function
resemble that of the individuals with EIF5A variants. From these
data we surmise that impaired synthesis of proteins enriched in
PPTs such as KMT2D and SF3B4 may underlie the phenotype(s)
caused by defective eIF5A. Genes encoding the highest level of
polyprolines display a strong association with biological processes
such as actin/cytoskeletal-associated functions, RNA splicing/
turnover, DNA binding/transcription and cell signalling6. Notably, variants in actin-encoding genes are known to cause human
developmental disorders with microcephaly49–51. Similarly mandibular and craniofacial features of spliceosomal disorders overlap with patients described here52. Other possible lines of
investigation could also be explored. For example, eIF5A regulates
pancreatic cancer metastasis by modulating expression of RhoA
and ROCK53. Germline variants in several Rho-GTPases cause
developmental disorders with microcephaly54,55. Recently it was
shown that hypusinated eIF5A promotes the efﬁcient expression
of a subset of mitochondrial proteins involved in the TCA cycle
and oxidative phosphorylation56. Exploring the effects of these
mutations on synthesis of mitochondrial proteins and function
could be an interesting avenue. Additionally, eIF5A has functions
in translation termination10,11 that we did not explore in this
study but which may contribute to this developmental disorder.
The importance of eIF5A in neurodevelopment is further
emphasised by the recent identiﬁcation of DHPS deﬁciency in
patients with a neurodevelopmental disorder with seizures and
speech and walking impairment (MIM # 618480)57. The role of
eIF5A in normal brain and craniofacial development has never
been examined before to the best of our knowledge and the
mechanism of how impaired eIF5A results in abnormal neurodevelopment will need to be studied in the future.
We demonstrated partial rescue of impaired eIF5A function
and its resultant phenotypes in yeast and zebraﬁsh models by
spermidine (Figs. 3a–c and 4c–d). In yeast, spermidine rescued
ribosome association defect and improved the polysome proﬁle
and PPT synthesis of the tested mutants. These effects are all
consistent with rescuing eIF5A function. However, the molecular
mechanism that underlies the rescue remains unclear. As eIF5A
expression and hypusination was not increased by spermidine
supplement (Fig. 3c), it appears spermidine is not acting via
hypusination alone. In agreement with this idea, eIF5A-80S
ribosome interaction was enhanced by spermidine (Fig. 3b). How
spermidine could boost remaining eIF5A function is not clear. As
spermidine rescued transient knockdown of eif5a in zebraﬁsh, it
may act similarly to the yeast model, or independently of eIF5A.
Of note, our zebraﬁsh model was based on transient knockdown
of eif5a, and stable germline mutants will need to be studied to
resolve these questions in the future. Importantly, spermidine
supplementation has been shown to be safe and well tolerated in
mice and humans58. It promotes longevity in yeast35 and may
extend the lifespan of mice and humans59,60. Higher spermidine
intake has been shown to be linked to lower mortality in
humans61. It has also been shown to protect against α-synuclein
neurotoxicity in fruit ﬂies62 and its levels are important for
memory-retrieval63 and age-related memory-associated brain
structures in rodents64. There is a growing interest in using
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spermidine as a therapeutic agent in conditions such as cognitive
decline65. Although the effects of spermidine may be independent
of its role in the synthesis of hypusinated eIF5A, our results raise
the interesting possibility of a potential future therapy for individuals with EIF5A variant-associated disease.
In summary, we have deﬁned a potentially treatable previously
undescribed human Mendelian disorder caused by EIF5A mutations that result in reduced eIF5A–ribosome interactions via
mutation-speciﬁc mechanisms. The phenotypes are likely
explained by impaired synthesis of speciﬁc PPT-rich proteins.
These ﬁndings uncover the role of eIF5A, and proteins with PPTs,
in human brain and craniofacial development. Our ﬁndings open
the avenue for future studies to identify the speciﬁc ‘hard to
synthesise’ proteins, and the biological processes, most dependant
on eIF5A function.
Methods
Ascertainment and exome sequencing analyses. Seven individuals from seven
unrelated families with heterozygous, de novo, variants in EIF5A were included in
this study after informed consents were obtained. The Central Manchester,
Cambridge South, and the Republic of Ireland RECs approved this study (02/CM/
238, 10/H0305/83 and GEN/284/12, respectively). Informed consent for research
studies from patients or their legal representatives was obtained in all cases. The
authors afﬁrm that human research participants provided informed consent for
publication of the images in Fig. 1. The patients were followed up by clinical
geneticists from France, the United Kingdom, and the USA. Variants were identiﬁed by trio whole-exome sequencing for the detection of an undiagnosed neurodevelopmental disorder associated with multiple congenital anomalies, following
published methodology for sample and library preparation, sequencing data production, analysis and interpretation66–69. For the interpretation process we also
considered the impact of variants on the preferentially expressed transcript
according to the GTEx project16 and the canonical protein according to UniProtKB18, and the tolerance of the gene to variation according to gnomAD19
scores, considering only high-quality non-ﬂagged variants present in the ‘only
controls' subset of this database. We considered variants in constrained coding
regions only (percentile > 90) according to Havrilla, et al.23. The clinical observations were gathered through the Matchmaker Exchange21 and GeneMatcher22
initiatives.
DNA samples from affected individual 3 and her parents, as well as informed
consent, were obtained for PCR and Sanger sequencing conﬁrmation. PCR was
performed using primers 5′-AATGGCAGGAGAGGGTGTTT-3′ and 5′-TGCA
GGTTCAGAGGATCACT-3′ and the GoTaq® Hot Start Green Master Mix 2x
(PROMEGA). PCR products were puriﬁed using an AxyPrep™ Mag PCR Clean-Up
kit (Axygen) and sequenced with a BigDye® Terminator v3.1 Cycle Sequencing kit
(Applied Biosystems) on an ABI 3730xl DNA sequencer (Applied Biosystems). The
resulting ABI ﬁles were examined using the Genome Assembly Program version
4.8b1. Similar Sanger sequencing methods were used to conﬁrm the presence of the
EIF5A variant in individual 1, and its absence in her parents.
In silico analysis of variants and MAGs. The evolutionary conservation analysis
of the residues affected by missense variants was performed using the eIF5A
canonical protein sequence from Homo sapiens (UniProtKB entry P63241), Mus
musculus (UniProtKB entry P63242), Gallus gallus (UniProtKB entry Q09121),
Danio rerio (UniProtKB entry Q6NX89, zebraﬁsh hereafter), Drosophila melanogaster (UniProtKB entry Q9GU68) and Saccharomyces cerevisiae (UniProtKB entry
P23301, yeast hereafter) using the ClustalWS alignment in Jalview70 Version 2.
2.10.5. These residues were modelled in the yeast 60S ribosomal subunit with A-site
tRNA, P-site tRNA and eIF5A (PDB entry 5GAK) using Chimera71 1.12.
We searched for all genes associated with microcephaly (MAG) deposited in
OMIM until 6 February 2018 using the search criteria ‘microcephaly (Entries with:
gene map locus; Preﬁxes: +, #; Retrieve: gene map)’. Data were then merged
between the OMIM search and the proline content of the human proteome
analysed by Morgan and Rubenstein30 and depicted in Supplementary Data 1.
Gene, variants, morpholinos and plasmid synthesis and expression. A yeast
expression plasmid for human eIF5A (heIF5A-WT) was designed to express the
human canonical protein sequence, but using the yeast optimised codon usage and
placed in the context of the yeast TIF51A (yeIF5A) 5′ and 3′ regions. This was
commercially synthesised (Epoch Life Sciences) and cloned into a pUC19 vector
(Supplementary Note 2), resulting in plasmid pAV2578 (Supplementary Table 1).
The gene was subsequently excised using XhoI and SpeI and cloned into SalI-andSpeI digested single-copy-number (sc) LEU2 (YCplac111), URA3 (YCplac33) and
high-copy-number (hc) LEU2 YEplac181 vectors, generating plasmids pAV2580,
pAV2592 and pAV2593 (Supplementary Table 1). The heIF5A sequence was
veriﬁed by Sanger sequencing at Euroﬁns Genomics using the M13 reverse primer.
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The variants p.T48N, p.G106R, p.R109Tfs*8 and p.E122K, detected in
individuals 1–3 and 7, respectively, were created through site-directed mutagenesis
using primers (Supplementary Table 2), the sc pAV2580 plasmid, and the
QuikChange Site-Directed Mutagenesis Kit (Agilent Technologies), following the
manufacturer’s instructions. An hc version of p.R109Tfs*8 was created in
pAV2593. The resulting plasmids pAV2584[heIF5A-T48N], pAV2585[heIF5AG106R], sc pAV2586[heIF5A-R109Tfs*8], pAV2587[heIF5A-E122K] and hc
pAV2590[heIF5A-R109Tfs*8 LEU2] (Supplementary Table 1) were veriﬁed by
Sanger sequencing as above.
For genetic knockdown of the eif5a gene in zebraﬁsh, an eif5a splice site
morpholino (MO) was synthesised (Gene Tools, Philomath, OR) for inhibition of the
eif5a gene (5′-AACCCTATCCAAACATTACCTTTGC-3′) as previously
published36. A standard control MO (5′-CCTCTTACCTCAGTTACAATTTATA-3′)
by Gene Tools was also used.
Leucocyte transformation and harvesting. Peripheral blood mononuclear cells
from one healthy, adult female (Control 1), one healthy, adult male (Control 2),
and Individual 3 were transformed by Epstein-Barr virus into LCLs following a
published protocol72. While ﬁve million LCLs from Individual 3 were harvested
from ﬁve cell culture ﬂasks under standard conditions, another ﬁve million LCLs
from the same individual and number of ﬂasks were treated for 6 h with 200 µg/mL
of puromycin before harvesting, and both type of samples were kept at −80 °C
before RNA extraction.
Yeast strain construction and growth assays. The J696 haploid yeast strain
deleted for both yeast eIF5A (yeIF5A) genes and whose growth is supported by a
plasmid bearing yeIF5A (Supplementary Table 3), as well as the yeIF5A plasmids
C3287 (pAV2569), C3288 (pAV2571) and C3294 (pAV2565), and hc PPT reporter
plasmids C4351 (pAV2566) and C4353 (pAV2570) (Supplementary Table 1) were
kindly provided by Thomas E. Dever, Laboratory of Gene Regulation and Development, National Institute of Child Health and Human Development, National
Institutes of Health, Bethesda, USA2,5.
To study the effect of heIF5A-WT and the variants in yeast, a series of yeast
strains was created by transformation and plasmid shufﬂing of the plasmids
described in Supplementary Table 1 into strain J696 to generate the strains
described in Supplementary Table 3.
To analyse the effect on yeast growth, heIF5A-WT and its variants, strains
GP7439 and GP7443 diploid for yeIF5A gene, and hybrid strains, GP7441, GP7447,
GP7448, GP7449 and GP7450 containing one yeIF5A copy and one heIF5A copy
(or yeIF5A control) were patched on minimal SD + tryptophan medium, and
replica-printed to SD+tryptophan+uracil+5-ﬂuoro-orotic acid plates to select for
loss of the WT yeIF5A and create haploid strains GP7440, GP7446, GP7444,
GP7455, GP7474 and GP7456 each bearing a different heIF5A or yeIF5A plasmid
as the sole source of eIF5A. Strains were 10-fold serially diluted and spotted on
appropriate selective media ± spermidine at indicated concentrations to record
growth phenotypes.
Protein extraction and WB. To study the effect of variants on humanised eIF5A
synthesis and hypusination, strains GP7444, GP7455, GP7456 and GP7474 were
grown in synthetic complete minus leucine (SC−LEU) medium, and strains
GP7469, GP7482, GP7484 and GP7485 were grown in synthetic complete minus
leucine and uracil (SC−LEU−URA) medium to mid-log phase at 30 °C. To study
the effect of variants on synthesis of HA-tagged Ldb17 and Eap1 reporters, all
strains between GP7490 and GP7493 and between GP7500 and GP7503 were
grown in SC drop-out medium containing dextrose (0.4%) and galactose (2%)
(SCGal-LEU-URA) for 24 h at 30 °C to induce expression of the PPT reporters.
Spermidine (1 mM) was added to media where indicated.
Ten OD600 units of cells of each strain were harvested, washed and resuspended
with 10% trichloroacetic acid, and broken with acid-washed glass beads (SigmaAldrich) in a bead-beater (Biospec Products) twice for 45 s. These cell extracts were
then centrifugated at 20,000g and the pellets resuspended in acetone twice. All
these procedures were carried out at 4 °C. After a ﬁnal centrifugation, pellets were
dried 10 min at 37 °C and solubilised in a protease inhibitor buffer (100 mM TrisHCl [pH 8.0], 1% SDS, 1 mM EDTA, 1 mM PMSF and 1 cOmplete™ protease
inhibitor tablet [Roche]) during 1 h at 37 °C. Then, NuPAGE® LDS Sample Buffer
4× (Invitrogen) and β-mercaptoethanol were added to the extracts, which were
subsequently boiled at 95 °C during 5 min and cooled immediately. After a ﬁnal
spin at 4 °C, supernatants were harvested and electrophoresis was carried out using
9–12 µL of protein extracts, NuPAGE™ 4–12% Bis-Tris gels (Invitrogen) and
NuPAGE™ MOPS SDS 20× running buffer (Invitrogen) during 50 min at 200 V.
The Precision Plus Protein™ All Blue Prestained Protein Standard (Bio-Rad
Laboratories Ltd, UK) was used as a molecular weight marker. Gels were blotted
onto Amersham™ Protan™ 0.45 µm nitrocellulose membranes (General Electric
Healthcare), and using Whatman™ 3 mm Chr chromatography paper (General
Electric Healthcare), NuPAGE™ 20× transfer buffer (Invitrogen), and XCell™ Blot
module (Invitrogen) during 1 h at 30 V. After blocking non-speciﬁc binding, the
membranes were incubated overnight at 4 °C with speciﬁc mouse anti-eIF5A
(1:10,000; BD Biosciences, #611977), rabbit anti-hypusine (1:1,000; EMD Millipore,
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#ABS1064), mouse anti-Pab1 (1:5000; EnCor Biotechnology, #MCA-1G1), mouse
anti-HA.11 (1:4000; BioLegend, #901513) or chicken anti-eIF2α (1:500; Cambridge
Research Biochemicals, custom designed). Then, the membranes were incubated
with a corresponding secondary ﬂuorescent labelled donkey anti-chicken (P/N:
926-32218), and goat anti-rabbit (P/N: 926-32211) or anti-mouse antibodies (P/N:
926-32350) (IRDye® 800CW; LI-COR Biosciences) and the signal was developed
using a LI-COR Odyssey® CLx Imaging System (LI-COR Biosciences) using default
parameters. The area of every band was selected to ﬁt it to the best curve of
ﬂuorescence.
The precise epitope recognised by the commercial eIF5A monoclonal antibody
is not known. It was raised to a protein 58–154 and our work shows it cross-reacts
with the R109Tfs*8 mutant (Supplementary Fig. 4), implying its epitope is between
58 and 108. As the antibody cross-reacts with all mutant forms tested here we
assume that G106 is not part of its binding site on eIF5A. Pab1 encoding the yeast
polyA-binding protein was used as a loading control for most assays. However,
Ldb17 with HA tag and Pab1 co-migrate in SDS-PAGE gels and some residual
ﬂuorescence remained for both proteins after stripping. Therefore, eIF2α
antibodies were used as a loading control for blots for experiments using Ldb17HA-expressing strains. Full scans of representative western blots shown in Figs. 2b,
d and 3c are depicted in Supplementary Figs. 9, 11 and 13.
Polysome proﬁle analysis. The GP7444, GP7455, GP7456 and GP7474 strains
were grown to mid-log phase at 30 °C in 80 ml of SC-LEU medium ± spermidine
(1 mM). Fifty millimolar of formaldehyde was added followed immediately by 15
ml of pre-made frozen media droplets. We used formaldehyde treatment to stabilise polysomes and bound factors rather than cycloheximide, because the latter
has been found to enhance eIF5A–ribosome interactions24. Cross-linking was then
carried out on ice water for 1 h before quenching with glycine (ﬁnal concentration
of 100 mM). Whole-cell extracts were prepared by bead beating in lysis buffer
(20 mM HEPES, 2 mM magnesium acetate, 100 mM potassium acetate, 0.5 mM
DTT), clariﬁed (10,000g 10 min) and separated on 15–50% sucrose gradients by
centrifugation at 40,000 r.p.m. for 2.5 h using a SW41 Beckman rotor. Gradients
were fractionated while scanning at A254 to visualise the indicated ribosomal
species. Polysome-to-monosome (P/M) and 60S/80S ratios were calculated by
comparing the areas under the 60S, 80S and polysome peaks. Gradient fractions
were TCA precipitated and underwent western blot analysis using antibodies as
described above as well as Rps3(uS3) (1:50,000) and Rpl35(uL29) (1:10,000) rabbit
polyclonal antibodies (a kind gift from Dr Martin Pool, University of Manchester).
Full scans of representative western blots shown in Figs. 2c and 3b are depicted in
Supplementary Figs. 10 and 12, respectively.
RNA extraction and quantitative real-time PCR (qRT-PCT). Total RNA was
extracted using RNeasy Mini kit (Qiagen) according to the manufacturer’s protocol
from one million LCLs of Control 1 and Control 2 each, and from one million,
untreated LCLs and one million puromycin-treated LCLs of Individual 3. RNA
concentration was measured using a NanoDrop 2000 spectrophotometer (Thermo
Scientiﬁc). RNA was reverse transcribed with random hexamer primers (Promega)
to generate cDNA using the M-MLV Reverse Transcriptase kit (Promega)
according to the manufacturer’s protocol. qRT-PCR reactions were performed on a
Bio-Rad CFX394 Real Time system (Bio-Rad) using Power SYBR Green PCR
Master mix (Applied Biosystems) and the forward 5′-GCCATGTAAGATCGTCGAGA-3′ and reverse 5′-GGAGCAGTGATAGGTACCCA-3′ EIF5A
primers (Sigma-Aldrich). The level of EIF5A mRNA was evaluated using a relative
quantiﬁcation approach (2−ΔCT method) with human GAPDH and its primers
5′-ATGGGGAAGGTGAAGGTCG-3′ and 5′-TAAAAGCAGCCCTGGTGACC-3′
as the internal reference. To detect if the frameshift-encoding transcript is
expressed, we performed bidirectional Sanger sequencing of Individual 3’s EIF5A
cDNA, obtained from both untreated and puromycin-treated LCLs, using the
aforementioned forward primer and reverse 5′-GCCTTGATTGCAACAGCTGC-3′
primer, as previously described.
Zebraﬁsh knockdown, staining and imaging. Zebraﬁsh husbandry was approved
by The University of Manchester Ethical Review Board and all experiments were
performed in accordance with UK Home Ofﬁce regulations (PPL P132EB6D7).
Four hundred picograms (in 1 nL) of either the eif5a or control MOs were injected
into 25–75 fertilised nacre embryos per condition, at the single-cell stage. Injected
embryos were incubated at 28 °C in standard E3 embryo medium (SE3EM) until
3 hpf and then split into two groups, one of them only in SE3EM and the other one
in SE3EM plus Spermidine (85558; Sigma-Aldrich) to a ﬁnal concentration of
1 µM. Both groups were incubated at 28 °C until 77 hpf, without renewing
the media.
At 77 hpf, larvae were terminated using 4% MS222 and ﬁxed for 1 h with 2%
paraformaldehyde, and then stained using a two-colour acid-free bone and
cartilage staining protocol73. Stained larvae groups were blinded to a manipulator,
mounted into 4% methylcellulose and imaged using a DFC7000 T Camera (Leica)
coupled to a M165 FC Microscope (Leica) using ×10 objective and LASX image
capture software (version 3.4.2; Leica). Head size and mandibles were measured as
depicted in Fig. 4a using ImageJ software (version 1.52j).
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Statistics. All statistics were calculated with either GraphPad Prism 8.3.0
(GraphPad Software) or SPSS v25 (IBM) and all experiments were carried out
using three biological (yeast and zebraﬁsh analyses) or technical (Individual 3’s
EIF5A RNA expression) replicates. Chi-square was performed to study the association between content of PPTs and MAGs. Signals of WBs from yeast extracts
were normalised to the mean signal across each blot for each antibody and for
loading variance between lanes using similarly normalised control antibody signals
as follows in Eq. (1):
ab ratio ¼

Tab
Cab
Tab ´ Mean Cab
=
¼
;
Mean Tab Mean Cab Mean Tab ´ Cab

ð1Þ

where Tab is the test antibody and Cab the control antibody. For hypusine
quantiﬁcation, eIF5A was used as its control antibody. Unpaired t-test against
control samples was performed for western blots from yeast extracts and for
Individual 3 EIF5A RNA expression. These results were depicted using bar plots,
which represent the mean (average) plus standard error of the mean with overlaid
data points representing independent experiments. Kruskal Wallis test with multiple comparisons was performed for zebraﬁsh analyses. These results were
depicted using dot plots and the longer horizontal line represents the median,
whereas the shorter horizontal lines are the 25th and 75th percentiles. A P value
below 0.05 was considered signiﬁcant, which is given at the top of each graph,
where relevant.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Data availability
All relevant data supporting the key ﬁndings of this study are available within the article
and its Supplementary Information ﬁles or from the corresponding author upon
reasonable request. Source data are provided with this paper.
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